65,437 trials
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16 — 62.9; 3.8 percentage of participants — p=<0.001
Liposarcoma
Primary: Cumulative Incidence Rate of Local Recurrence and Competing Risks (All Patients) — 16.89; 10.42 percentage of participants
Autism Spectrum Disorder
Primary: Maximum Plasma Concentration (Cmax) of Balovaptan — 74.83; 97.44; 79.67 ng/mL
Vascular Disease
Primary: Technical and Global Performance of the Surgical Trainee in Real Life Procedures — 39.36; 28.42; 23.09; 63.51 score on a scale
Vascular Malformations · Vascular Malformation Peripheral · Venous Malformation
Primary: Volume Difference of Malformation to Baseline (no Compression) While Wearing Compression Stockings Class I and II Determined by MRI — 16.38; 23.7 ml
Multiple Myeloma
Primary: Mean Multiple Myeloma Lesions Detected — 4.6; 4.4; 1.1; 1.0 number of lesions
Dyslipidemia
Primary: Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) — -17.9; -25.0; -26.6; -2.1 Percent Change — p=<0.0001
Symptomatic Severe Aortic Stenosis
Primary: Major Vascular Complications — 4.3 percentage of participants
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Patient Global Impression of Severity (PGI-S) Score in Cohort A Participants at Approximately 30 Minutes of Previous Dose of Inhaled Treprostinil…
Breast Cancer Female
Primary: Self-Reported Self-Efficacy for Communicating About Sexual Health Issues — 8.5; 8.8 score on a scale
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Cystic Fibrosis
Primary: The Primary Objective is to Assess the Safety of 13C Urea Administered by Inhalation. — 0; 0 adverse events
Juvenile Dermatomyositis
Primary: Responder Status Defined as 20% Improvement in at Least 3 Core Set Variables With no More Than 1 of the Remaining Variables, (Muscle Strength Excluded), Worsened by >…
Atrial Fibrillation · Alcohol
Primary: Number of Participants With Atrial Fibrillation Induction — 22; 24 Participants
Cardiovascular Diseases · Cardiovascular Abnormalities · Calcifications, Vascular
Primary: Change in Log CAC Volume Score From Baseline to Week 52 for the Combined Dose Groups vs Placebo — 1.11; 1.20 ratio